Somavaratan
(Somapacitan)Phase 3Small molecule
Novo NordiskSomapacitan is used to treat growth hormone deficiency in children and adults. It helps people who don't produce enough growth hormone naturally to grow and develop normally.[1] Somavaratan is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Somavaratan is one of 67 small molecule programs targeting Growth delay. It is currently in Phase 3.
5
Indications
20
Total Trials
7
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
364 competitors in Growth
#DrugCompanyPhaseTrials
1Somavaratan
Novo NordiskPhase 3
Lovenox
SanofiPreclinical
Zyloprim
Alnylam PharmaceuticalsPreclinical
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Aricept
EisaiPreclinical
Herceptin
OOrganon and Co
Preclinical
Glucophage
EMD SeronoPreclinical
Glucagon
XXeris Pharmaceuticals
Preclinical
Trental
VValidus Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Growth Hormone Deficiency9 trials
Treatment3 trials
Absorption1 trial
Hepatic Impairment1 trial
Impaired Renal Function1 trial
5 more indications
Skin1 trial
Children1 trial
SGA1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Somapacitan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Growth Hormone Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company